Aviva PLC lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 157.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 61,918 shares of the company's stock after acquiring an additional 37,826 shares during the period. Aviva PLC owned 0.06% of Neurocrine Biosciences worth $8,452,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. HighPoint Advisor Group LLC increased its position in shares of Neurocrine Biosciences by 4.1% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,446 shares of the company's stock worth $334,000 after purchasing an additional 96 shares during the last quarter. Huntington National Bank increased its position in shares of Neurocrine Biosciences by 73.5% during the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after acquiring an additional 97 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Neurocrine Biosciences by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 28,100 shares of the company's stock valued at $3,836,000 after acquiring an additional 100 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in shares of Neurocrine Biosciences by 0.5% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 22,361 shares of the company's stock valued at $3,052,000 after acquiring an additional 103 shares during the period. Finally, Metis Global Partners LLC boosted its position in shares of Neurocrine Biosciences by 4.3% during the 4th quarter. Metis Global Partners LLC now owns 2,548 shares of the company's stock worth $348,000 after purchasing an additional 104 shares during the period. Institutional investors and hedge funds own 92.59% of the company's stock.
Insiders Place Their Bets
In other news, insider Ingrid Delaet sold 623 shares of the business's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $149.29, for a total transaction of $93,007.67. Following the completion of the sale, the insider now owns 3,442 shares in the company, valued at $513,856.18. The trade was a 15.33 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kyle Gano sold 65,000 shares of the business's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the sale, the chief executive officer now directly owns 135,392 shares of the company's stock, valued at $19,157,968. This represents a 32.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 232,906 shares of company stock valued at $33,869,030. 4.30% of the stock is currently owned by insiders.
Neurocrine Biosciences Stock Up 3.7 %
Neurocrine Biosciences stock traded up $3.35 during mid-day trading on Monday, reaching $94.22. The company had a trading volume of 192,324 shares, compared to its average volume of 1,027,838. The firm has a market cap of $9.39 billion, a price-to-earnings ratio of 28.64, a PEG ratio of 0.77 and a beta of 0.33. The company has a 50 day moving average of $111.68 and a 200-day moving average of $123.06. Neurocrine Biosciences, Inc. has a 52 week low of $84.23 and a 52 week high of $157.98.
Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. On average, analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.
Neurocrine Biosciences announced that its board has initiated a share repurchase program on Friday, February 21st that allows the company to buyback $500.00 million in shares. This buyback authorization allows the company to repurchase up to 4.2% of its shares through open market purchases. Shares buyback programs are often an indication that the company's board believes its shares are undervalued.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an "overweight" rating in a report on Wednesday, March 26th. Deutsche Bank Aktiengesellschaft started coverage on Neurocrine Biosciences in a report on Tuesday, February 11th. They issued a "hold" rating and a $138.00 target price for the company. Piper Sandler restated an "overweight" rating and set a $160.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 23rd. UBS Group decreased their price objective on Neurocrine Biosciences from $154.00 to $137.00 and set a "buy" rating for the company in a research note on Friday, April 4th. Finally, William Blair restated an "outperform" rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Four equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of "Moderate Buy" and a consensus price target of $163.00.
Read Our Latest Stock Analysis on Neurocrine Biosciences
About Neurocrine Biosciences
(
Free Report)
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Further Reading
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
